Open AccessArticle
VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy
by
Maria Christina Tsourlakis, Puya Khosrawi, Philipp Weigand, Martina Kluth, Claudia Hube-Magg, Sarah Minner, Christina Koop, Markus Graefen, Hans Heinzer, Corinna Wittmer, Guido Sauter, Till Krech, Waldemar Wilczak, Hartwig Huland, Ronald Simon, Thorsten Schlomm and Stefan Steurer
Cited by 6 | Viewed by 6804
Abstract
The VEGFR-1 is suggested to promote tumor progression. In the current study we analyzed prevalence and prognostic impact of the VEGFR-1 by immunohistochemistry on a tissue microarray containing more than 3000 prostate cancer specimens. Results were compared to tumor phenotype, ETS-related gene (ERG)
[...] Read more.
The VEGFR-1 is suggested to promote tumor progression. In the current study we analyzed prevalence and prognostic impact of the VEGFR-1 by immunohistochemistry on a tissue microarray containing more than 3000 prostate cancer specimens. Results were compared to tumor phenotype, ETS-related gene (ERG) status, and biochemical recurrence. Membranous VEGFR-1 expression was detectable in 32.6% of 2669 interpretable cancers and considered strong in 1.7%, moderate in 6.7% and weak in 24.2% of cases. Strong VEGFR-1 expression was associated with
TMPRSS2:ERG fusion status as determined by fluorescence
in situ hybridization (FISH) and immunohistochemistry (
p < 0.0001 each). Elevated VEGFR-1 expression was linked to high Gleason grade and advanced pT stage in
TMPRSS2:ERG negative cancers (
p = 0.0008 and
p = 0.001), while these associations were absent in
TMPRSS2:ERG positive cancers. VEGFR-1 expression was also linked to phosphatase and tensin homolog (
PTEN) deletions. A comparison with prostate specific antigen (PSA) recurrence revealed that the 1.7% of prostate cancers with the highest VEGFR-1 levels had a strikingly unfavorable prognosis. This could be seen in all cancers, in the subsets of
TMPRSS2:ERG positive or negative,
PTEN deleted or undeleted carcinomas (
p < 0.0001 each). High level VEGFR-1 expression is infrequent in prostate cancer, but identifies a subgroup of aggressive cancers, which may be candidates for anti-VEGFR-1 targeted therapy.
Full article
►▼
Show Figures